The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

Abstract

Inhibition of IGF-IR signaling synergistically enhances the sensitivity of SCLC to etoposide and carboplatin. This enhancement in sensitivity to chemotherapy tightly correlates with inhibition of PI3K-Akt activation. Future SCLC clinical trials incorporating IGF-IR inhibitors alone or in combination with other kinase inhibitors should include assessment of PI3K-Akt activity as a pharmacodynamic end-point.

References

Page 1

	Year	Citations
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. James Carmichael, William DeGraff, Adi F. Gazdar, PubMed PharmacotherapyChemistryDrug ResistanceClonogenic AssaysMedicinal Chemistry	1987	3.8K
Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara, New England Journal of Medicine	2002	1.4K
Establishment and identification of small cell lung cancer cell lines having classic and variant features Desmond N. Carney, Adi F. Gazdar, Gerold Bepler, Lung Cancer Tumor BiologyTumor HeterogeneityMedicinePathologyCancer Genomics	1986	912
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells Ryo Fukuda, Kiichi Hirota, Fan Fan, Journal of Biological Chemistry	2002	820
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors Constantine S. Mitsiades, Nicholas Mitsiades, Ciaran J. McMullan, Cancer Cell Hematological MalignancySolid TumorsMedicineReceptor Tyrosine KinaseImmunology	2004	610
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis Hong‐Ren Yu, M R Spitz, Jehangir Mistry, JNCI Journal of the National Cancer Institute	1999	557
In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti, Cancer Cell Cancer ResearchMedicineReceptor Tyrosine KinaseVivo Antitumor ActivityNvp-aew541—a Novel	2004	535
Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth Ada Girnita, Leonard Girnita, Fabrizio Del Prete, Cancer Research	2004	357
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Douglas Burtrum, Zhenping Zhu, Dan Lu, PubMed Human GrowthImmunologyInsulin BindingImmunotherapyTumor Biology	2003	349
An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Erin K. Maloney, Jennifer L McLaughlin, Nancy E Dagdigian, PubMed Cancer Cell ProliferationPotent InhibitorImmunologyImmunoeditingIgf-ir Function	2003	309

Page 1